MontageTechnology is a leading fabless semiconductor provider focusing on the data center and smart home entertainment markets. In the data center market, Montage delivers high-performance, secure and controllable CPU, memory module and memory interface solutions for new generation servers. In the smart home entertainment market, Montage provides highly integrated and customizable OTT/STB total solutions for home entertainment, and offers feature-rich, cost-effective consumer IoT solutions for wireless connectivity everywhere at home. Montage’s sophisticated technology platform allows it to deliver integrated solutions that meet the expanding needs of customers through continuous innovation, efficient design and rapid product development.
Founded in 1991, Mindray is one of the leading global providers of medical devices and solutions. Headquartered in Shenzhen, China, Mindray possesses a sound global R&D, marketing and service network with subsidiaries and branch offices in 32 countries in North and Latin America, Europe, Africa and Asia-Pacific, as well as 31 branch offices in China. To date, Mindray has nearly 7,600 employees.Today, Mindray’s products and services can be found in healthcare facilities in over 190 countries and regions. In China, Mindray’s products and solutions can be found in nearly 110,000 medical institutions and 99% of Class A tertiary hospitals.
In the process of dismantling the offshore structure of Mindray, V-Capital received the shares held by the foreign shareholders of Mindray by setting fund, and became the shareholder of Mindray before its domestic securitization. At present, the IPO of Mindray has entered the final stage.
Founded in 2009, iDreamSky is headquartered in Shenzhen. It is a leading Chinese digital entertainment platform, having developed top-quality games and the Play Together offline store to create a 24-hour online and offline entertainment community.
iDreamSky's games are a driving force behind Chinese games, and its products have stood the test of time. iDreamSky has expanded from publishing games to developing them as well. We have released Gardenscapes, Homescapes, Little Animal Star, Global Operations, Glory Stars, Subway Surfers, Temple Run 2, Monument Valley, and other great titles.
Weimob is a WeChat third-party technology development and service provider. It provides customers with a full range of integrated solutions through WeChat platforms such as SaaS, precision marketing, social e-commerce, and financial technology. The company's current business mainly includes SaaS software and precision marketing. After four years of development, the company has 2,500 employees, more than 1,300 agents worldwide, and more than 2.2 million settled merchants. It has become the leading third-party service market in the WeChat ecosystem.
V-Capital set up an M&A fund with the major shareholder of the target, in order to assist the company's actual controllers in optimizing the shareholder structure and strengthening its control before the target’s Hong Kong securitization. While set adequate credit enhancement measures, we fully shared the growth of the target’s equity.
Founded in March 2010, Asieris Pharmaceuticals(688176.SH), is a global innovative pharma company specializing in new drugs for the treatment of genitourinary tumors and other major diseases. It strives to improve human health and help people live a more dignified life. It aims to become a global pharma leader that integrates R&D, manufacturing, and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
Asieris has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Founded in 2016, MGI is committed to building core tools and technology to lead life science through intelligent innovation. With a focus on R&D, production and sales of DNA sequencing instruments, reagents, and related products, MGI provides real-time, panoramic, and full-life-cycle equipment and systems for precision medicine, precision agriculture, precision healthcare and other relevant industries. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, medical imaging, and laboratory automation.
As of December 31, 2021, MGI has 2,050 employees, 35% of whom are R&D personnel. Founded in 2016, MGI operates in more than 80 countries and regions, serving more than 1,300 customers. It has established scientific research and production bases, global training and service network in many countries and regions around the world. MGI is one of the few companies in the world that can independently develop and mass-produce clinical high-throughput gene sequencers. Providing real-time, comprehensive, life-long solutions, its vision is to lead life science innovation.
